Paolo Marino

Paolo Marino

Auto-generated profile, based on publicly available information

Paolo Marino

Istituto Iperbarico

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Journal of the American Society of Echocardiography
Verified
Journal Article
Open access
SNSherif F. Nagueh
Sherif F. Nagueh
OSOtto A. Smiseth
Otto A. Smiseth
CAChristopher P. Appleton
Christopher P. Appleton
BBBenjamin F. Byrd
Benjamin F. Byrd
HDHisham Dokainish
Hisham Dokainish
AWAlan D. Waggoner
Alan D. Waggoner

1 February 2009 in Journal of the American Society of Echocardiography
Verified
Journal Article
Open access
SNSherif F. Nagueh
Sherif F. Nagueh
CAChristopher P. Appleton
Christopher P. Appleton
TGThierry C. Gillebert
Thierry C. Gillebert
PMPaolo N. Marino
Paolo N. Marino
JOJae K. Oh
Jae K. Oh
AEArturo Evangelista
Arturo Evangelista

11 April 2007 in European Heart Journal
Verified
Journal Article
Open access
PDF file
WPWalter J. Paulus
Walter J. Paulus
CTCarsten Tschöpe
Carsten Tschöpe
JSJohn E. Sanderson
John E. Sanderson
CRCesare Rusconi
Cesare Rusconi
FFFrank A. Flachskampf
Frank A. Flachskampf
DBDirk L. Brutsaert
Dirk L. Brutsaert
Diastolic heart failure (DHF) currently accounts for more than 50% of all heart failure patients. DHF is also referred to as heart failure with normal left ventricular (LV) ejection fraction (HFNEF) to indicate that HFNEF could be a precursor of heart failure with reduced LVEF. Because of improved cardiac imaging and because of widespread clinical use of plasma levels of natriuretic peptides, diagnostic criteria for HFNEF needed to be updated. The diagnosis of HFNEF requires the following conditions to be satisfied: (i) signs or symptoms of heart failure; (ii) normal or mildly abnormal systolic LV function; (iii) evidence of diastolic LV dysfunction. Normal or mildly abnormal systolic LV function implies both an LVEF > 50% and an LV end-diastolic volume index (LVEDVI) 16 mmHg or mean pulmonary capillary wedge pressure >12 mmHg) or non-invasively by tissue Doppler (TD) (E/E′ > 15). If TD yields an E/E′ ratio suggestive of diastolic LV dysfunction (15 > E/E′ > 8), additional non-invasive investigations are required for diagnostic evidence of diastolic LV dysfunction. These can consist of blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, electrocardiographic evidence of atrial fibrillation, or plasma levels of natriuretic peptides. If plasma levels of natriuretic peptides are elevated, diagnostic evidence of diastolic LV dysfunction also requires additional non-invasive investigations such as TD, blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, or electrocardiographic evidence of atrial fibrillation. A similar strategy with focus on a high negative predictive value of successive investigations is proposed for the exclusion of HFNEF in patients with breathlessness and no signs of congestion. The updated strategies for the diagnosis and exclusion of HFNEF are useful not only for individual patient management but also for patient recruitment in future clinical trials exploring therapies for HFNEF.

4 August 2008 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SNSherif F. Nagueh
Sherif F. Nagueh
CAChristopher P. Appleton
Christopher P. Appleton
TGThierry C. Gillebert
Thierry C. Gillebert
PMPaolo N. Marino
Paolo N. Marino
JOJae K. Oh
Jae K. Oh
AEArturo Evangelisa
Arturo Evangelisa
The assessment of left ventricular (LV) diastolic function should be an integral part of a routine examination, particularly in patients presenting with dyspnea or heart failure. About half of patients with new diagnoses of heart failure have normal or near normal global ejection fractions (EFs). These patients are diagnosed with “diastolic heart failure” or “heart failure with preserved EF.” 1 The assessment of LV diastolic function and filling pressures is of paramount clinical importance to distinguish this syndrome from other diseases such as pulmonary disease resulting in dyspnea, to assess prognosis, and to identify underlying cardiac disease and its best treatment.

1 May 2006 in JACC
Verified
Journal Article
Closed access
EOEraldo Occhetta
Eraldo Occhetta
MBMiriam Bortnik
Miriam Bortnik
AMAndrea Magnani
Andrea Magnani
GFGabriella Francalacci
Gabriella Francalacci
CPCristina Piccinino
Cristina Piccinino
PMPaolo Marino
Paolo Marino

28 October 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
ENEliano Navarese
Eliano Navarese
PMPaolo Marino
Paolo Marino
Several randomized trials and a previous meta-analysis have shown significant benefits from Gp IIb-IIIa inhibitors, especially abciximab. Recent randomized trials (BRAVE-3 and HORIZON trials) have shown no benefits from adjunctive Gp IIb-IIIa inhibitors on the top of clopidogrel administration. However, the relatively low mortality may have hampered the conclusion of these recent trials. Thus, the aim of the current study was to perform an update meta-analysis of randomized trials on adjunctive Gp IIb-IIIa inhibitors in primary angioplasty, and to evaluate by meta-regression analysis, whether the results may be related to risk profile. We obtained results from all randomized trials evaluating the benefits of adjunctive Gp IIb-IIIa inhibitors among STEMI patients undergoing primary angioplasty. The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL) from January 1990 to September 2008. The following key words were used: randomized trial, myocardial infarction, reperfusion, primary angioplasty, Gp IIb-IIIa inhibitors, abciximab, tirofiban, and eptifibatide. Clinical endpoint was mortality at 30 days. Major bleeding complications were assessed as safety endpoint. No language restriction was applied. A total of 16 randomized trials were finally included in the meta-analysis, involving 10 085 patients (5094 or 50.5% in the Gp IIb-IIIa inhibitors group and 4991 or 49.5% in the control group. Gp IIb-IIIa inhibitors did not reduce 30 day mortality (2.8 vs. 2.9%, P = 0.75) or re-infarction (1.5 vs. 1.9%, P = 0.22), but were associated with higher risk of major bleeding complications (4.1 vs. 2.7%, P = 0.0004). However, we observed a significant relationship between patient's risk profile and benefits from adjunctive Gp IIb-IIIa inhibitors in terms of death (P = 0.008) but not re-infarction (P = 0.25). This meta-analysis shows a significant relationship between benefits in mortality from Gp IIb-IIIa inhibitors and patient's risk profile. Thus, Gp IIb-IIIa inhibitors should be strongly considered among high-risk patients.